The Benefits of Sacubitril-Valsartan in Low Ejection Fraction Heart Failure
نویسندگان
چکیده
Heart failure (HF) is the cause of impaired exercise capacity due to insufficient peripheral blood flow. Development natriuretic peptide (NP) through inhibition neprilysin enzyme therapeutic target in HF. Treatment with sacubitril/valsartan has been shown significantly reduce mortality and hospitalization rehospitalization rates for HF compared enalapril. Sacubitril/valsartan may provide significant additional benefit patients.
منابع مشابه
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
OBJECTIVE Chronic heart failure with reduced ejection fraction (HF-REF) represents a major public health issue and is associated with considerable morbidity and mortality. We evaluated the cost-effectiveness of sacubitril/valsartan (formerly LCZ696) compared with an ACE inhibitor (ACEI) (enalapril) in the treatment of HF-REF from the perspective of healthcare providers in the UK, Denmark and Co...
متن کاملInfluence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction
Left ventricular ejection fraction (LVEF) remains the most commonly utilized metric of cardiac function and has been related to outcomes in patients across the spectrum of heart failure (HF). In patients with HF and reduced ejection fraction (EF), LVEF had been shown to be predictive of cardiovascular death, HF hospitalization, and all-cause mortality in a relatively linear fashion, with those ...
متن کاملChanging the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination
Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk of morbidity and mortality. Sacubitril valsartan (previously known as LCZ696) is a new oral agent approved for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction. It is described as the first in class angiotensin receptor neprilysin inhibitor (ARNI) sin...
متن کاملEjection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients.
BACKGROUND Sacubitril/Valsartan has been shown to improve mortality and reduce hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF). The effect of Sacubitril/Valsartan on ejection fraction (EF) and reverse remodeling parameters have not been previously described. METHODS We performed a single-center, retrospective, cohort study of HFrEF patients (n=48) who we...
متن کاملCost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
OBJECTIVES The objective of this study was to determine the cost-effectiveness and cost per quality-adjusted life year (QALY) gained of sacubitril-valsartan relative to enalapril for treatment of heart failure with reduced ejection fraction (HFrEF). BACKGROUND Compared with enalapril, combination angiotensin receptor-neprilysin inhibition (ARNI), as is found in sacubitril-valsartan, reduces c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: A?BÜ ?zzet Baysal t?p fakültesi dergisi
سال: 2022
ISSN: ['1305-4392']
DOI: https://doi.org/10.47493/abantmedj.1182158